Feldene® (Piroxicam): Forms, Dosage, Arthritis Indications & Critical Safety Guide

FELDENE® (Piroxicam) — Consolidated Drug Monograph

1. Disclaimer

This monograph is provided for general educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment, and it does not replace the official prescribing information supplied with the specific Feldene product available in your country. Piroxicam is associated with potentially serious gastrointestinal, cardiovascular, renal, hepatic, allergic, and severe cutaneous risks; the appropriate product, dose, duration, and route depend on the individual patient and the pharmaceutical form.

We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.

Because Feldene exists in several pharmaceutical forms, and because regulatory information can differ between countries and may change over time, the package leaflet and regulatory labeling applicable to the exact product, strength, and country of purchase must always take precedence over any general drug review. Use of any Feldene (piroxicam) formulation should be under medical supervision, using the lowest effective dose for the shortest duration consistent with the treatment goals.

2. Summary

Feldene® is the originator brand of piroxicam, a long-acting non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class, with anti-inflammatory, analgesic, and antipyretic activity. It is approved by the U.S. FDA for the symptomatic relief of osteoarthritis and rheumatoid arthritis; several non-U.S. labels (including the UK SmPC and the Egyptian Pfizer product information) additionally include ankylosing spondylitis.

Piroxicam has a very long plasma half-life of approximately 50 hours, allowing once-daily dosing but causing drug accumulation and only reaching steady state after 7–12 days. Because of a comparatively high risk of serious gastrointestinal and cutaneous adverse reactions (as recognized by the European Medicines Agency Article 31 referral), current European product information explicitly states that piroxicam is not a first-line NSAID.

Feldene is marketed globally in multiple forms — 10 mg and 20 mg oral capsules, dispersible tablets, fast-dissolving “Flash/Melt” 20 mg tablets, 20 mg suppositories, 20 mg/mL IM injection, and 0.5% topical gel — with Pfizer as the originator company. In Egypt, several of these presentations are (or have been) available, but current registration status and pack sizes should be verified through the Egyptian Drug Authority (EDA).

3. Brand Name

Feldene® (and the fast-dissolving/orodispersible line marketed as Feldene Flash® or, in some markets, Feldene Melt®).

The active pharmaceutical ingredient in all presentations is piroxicam. The Feldene name is used internationally for oral, rectal, injectable, and topical products; the marketing authorisation holder may differ from country to country.

4. Category

Pharmacological class: Non-steroidal anti-inflammatory drug (NSAID)
Chemical/therapeutic class: Oxicam derivative
ATC classification (systemic): M01AC01 – Piroxicam
Topical preparations are classified separately because the route and use differ.
Piroxicam exhibits anti-inflammatory, analgesic, and antipyretic activity. It is not an antimicrobial agent and has no antibacterial, antifungal, antiviral, or antiparasitic activity.

5. Active Ingredient

Piroxicam — chemical name: 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide.

Piroxicam is a non-selective, reversible inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostanoid synthesis and thereby lowering prostaglandin-mediated pain, inflammation, and fever.

6. Pharmaceutical Form & Strength

Feldene has been marketed in the following forms (globally):

Pharmaceutical form	Strength
Hard oral capsule	10 mg, 20 mg
Dispersible tablet	10 mg, 20 mg (market-dependent)
Fast-dissolving / orodispersible tablet (Flash / Melt)	20 mg
Rectal suppository	20 mg
Solution for intramuscular injection	20 mg/mL (1 mL ampoule)
Topical gel	0.5% w/w (5 mg piroxicam per gram)

In the U.S., FDA-approved dosage forms of Feldene are limited to 10 mg and 20 mg oral capsules.

In Egypt, historically documented Pfizer presentations include:

Trade name (Egypt)	Form	Strength	Pack size
Feldene 0.5% topical gel	Topical gel	0.5% (5 mg/g)	15 g tube
Feldene 10 mg caps	Hard capsules	10 mg	20 caps
Feldene 10 mg dispersible tablet	Dispersible tablets	10 mg	20 tabs
Feldene 20 mg caps	Hard capsules	20 mg	10 caps
Feldene 20 mg dispersible tablet	Dispersible tablets	20 mg	10 tabs
Feldene 20 mg suppository	Suppositories	20 mg	5 supp
Feldene 20 mg/mL i.m. ampoule	Solution for IM injection	20 mg/mL	3 or 6 amps
Feldene Flash 20 mg	Fast-dissolving/orodispersible tablets	20 mg	10 tabs

The current registration status, manufacturer, pack size, and continuous availability of any specific presentation should be verified through the Egyptian Drug Authority (EDA) database and the current Pfizer Egypt leaflet.

7. Manufacturer & Marketing Authorization Holder

Originator / Brand owner: Pfizer Inc., New York, NY, USA. Feldene was initially approved in the U.S. in 1982.
UK Marketing Authorisation Holder (Feldene 10 mg capsules and Feldene Melt 20 mg tablets): Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom.
Egypt: Marketed under the Pfizer brand (Pfizer Egypt S.A.E.), with manufacture or import/distribution depending on the specific presentation.
The exact legal Marketing Authorisation Holder and manufacturing site for any Egyptian presentation should be confirmed against the product package and the current EDA registration record.

8. Mechanism of Action

Like other NSAIDs, piroxicam’s mechanism is not completely understood but is primarily attributed to reversible, non-selective inhibition of cyclooxygenase (COX-1 and COX-2), decreasing the synthesis of prostaglandins that mediate pain, inflammation, and fever. Prostaglandins sensitize afferent nerves and potentiate bradykinin-induced pain; peripheral prostaglandin depletion is central to piroxicam’s analgesic and anti-inflammatory action.

Piroxicam also has additional anti-inflammatory actions described in Pfizer product information, including:

• Inhibition of neutrophil aggregation,
• Inhibition of polymorphonuclear leukocyte and monocyte migration,
• Inhibition of lysosomal enzyme release from stimulated leukocytes.

Because prostaglandins have physiological roles in gastric mucosal protection, renal perfusion, platelet function, cardiovascular homeostasis, and the fetal circulation, COX inhibition also explains many of piroxicam’s most important adverse effects.

9. Spectrum of Activity

Not applicable in the antimicrobial sense — piroxicam has no antibacterial, antifungal, antiviral, or antiparasitic spectrum.

Its pharmacological spectrum comprises:

• Anti-inflammatory effects in synovial and other inflamed tissues,
• Analgesic effects (predominantly peripheral, with a central contribution),
• Antipyretic effects (via inhibition of hypothalamic prostaglandin synthesis),
• Weak, transient antiplatelet effects (of lesser magnitude and duration than aspirin).

Systemic piroxicam provides symptomatic relief only; it does not cure underlying rheumatologic disease or halt structural progression of rheumatoid arthritis.

10. Pharmacokinetics

Absorption. Piroxicam is well absorbed after oral and rectal administration; oral bioavailability approaches 100%. Plasma concentrations peak approximately 3–5 hours after a conventional oral dose. Food slightly delays the rate of absorption but does not significantly change the overall extent. The piroxicam-β-cyclodextrin fast-dissolving formulation (Feldene Flash/Melt) has a shorter Tmax (approximately 1.4–2 hours), enabling faster onset of analgesia; pharmacokinetic studies show it is bioequivalent to the conventional capsule after repeated dosing.

Distribution. Piroxicam is highly plasma-protein bound (~99%, mainly to albumin). Apparent volume of distribution is approximately 0.14 L/kg. It distributes into synovial fluid (approximately 40–50% of plasma concentration) and into breast milk at low levels (about 1–3% of maternal plasma concentration).

Metabolism. Piroxicam is extensively metabolized in the liver, predominantly by CYP2C9. A major metabolic pathway is hydroxylation of the pyridyl ring, followed by glucuronide conjugation and urinary elimination. The principal metabolite (5′-hydroxypiroxicam) is pharmacologically inactive.

Elimination. Plasma half-life is approximately 50 hours, allowing once-daily dosing but resulting in significant accumulation and only reaching steady state after 7–12 days. Less than 5% of the daily dose is excreted unchanged in urine and feces; most drug is eliminated after metabolism as glucuronide conjugates. Clearance is reduced in CYP2C9 poor metabolizers (e.g., CYP2C9*3/*3) and in the presence of CYP2C9 inhibitors such as fluconazole.

11. Indications

U.S. FDA-approved (all systemic forms):

• Relief of the signs and symptoms of osteoarthritis
• Relief of the signs and symptoms of rheumatoid arthritis

Additional indications recognized in other regulatory jurisdictions (e.g., UK SmPC, Egyptian Pfizer product information):

• Ankylosing spondylitis (systemic forms)
• Acute musculoskeletal disorders — sprains, strains, bursitis, tendonitis (short-term)
• Acute gout (short course)
• Primary dysmenorrhea, postoperative pain, dental pain (some markets)
• Feldene 0.5% topical gel: symptomatic relief of localized musculoskeletal pain and inflammation — including superficial tendinitis, sprains, bruises, and lower-back pain

The UK SmPC explicitly states that Feldene is not a first-line NSAID because of its safety profile.

The Egyptian Pfizer IM injection (20 mg/mL) is intended primarily for initial short-term treatment (typically 1–2 days) of acute inflammatory conditions or acute exacerbations of chronic inflammatory disease, after which continuation should be with oral or rectal forms.

12. Administration

General principle. Use the lowest effective dose for the shortest duration consistent with the individual patient’s treatment goals. Because of the long half-life, therapeutic effect should not be reassessed for at least 2 weeks.

• Oral capsules / dispersible tablets / Flash tablets: 20 mg once daily (may be divided if desired). Take with or after food and a full glass of water; avoid lying down for 15–30 minutes to reduce esophageal irritation.
• Feldene Flash/Melt (fast-dissolving): Place on the tongue; it dissolves in saliva and is then swallowed, with or without water. Useful in patients with dysphagia.
• Suppository (20 mg): 20 mg once daily, preferably in the evening; useful when oral administration is not feasible.
• Intramuscular injection (20 mg/mL, 1 mL ampoule): 20 mg once daily as a deep IM injection into a large muscle (the Egyptian Pfizer labeling specifies the upper outer quadrant of the buttock). Reserved for the acute phase (1–2 days), then switch to oral or rectal continuation. Not for intravenous administration.
• Topical gel 0.5%: Apply a thin layer with gentle massage 2–4 times daily to the affected area; wash hands afterward. The Egyptian Pfizer information recommends 2–4 daily applications; alternative Pfizer labeling suggests approximately 1 g (about 3 cm of gel) per application. Do not apply to broken skin, eyes, or mucous membranes, and do not use occlusive dressings.

Critical rule. The total daily piroxicam dose from all formulations combined (capsules + dispersible + Flash + suppository + injection) must not exceed the recommended maximum daily dose — different Feldene forms are not additive as if they were different drugs.

13. Method of Preparation

Most Feldene formulations require no home reconstitution or compounding:

• Capsules: swallow whole with water — no preparation.
• Dispersible tablets: disperse in approximately 50 mL (about half a glass) of water, stir, and drink immediately; rinse the glass.
• Feldene Flash / orodispersible tablets: no preparation — dissolves spontaneously on the tongue; may be taken with or without water.
• Suppositories: remove from foil before rectal insertion; may be moistened with water if needed.
• IM ampoules: supplied as a ready-to-use sterile solution. Inspect for particulate matter and discoloration before use. Do not mix with other drugs in the same syringe.
• Topical gel: ready to use; do not dilute.

Instructions on the specific local package leaflet always take precedence, because formulations marketed under similar names are not necessarily pharmaceutically identical between countries.

14. Contraindications

Systemic piroxicam is contraindicated in patients with:

• Known hypersensitivity (including anaphylactic reactions and serious skin reactions) to piroxicam or any excipient
• History of asthma, urticaria, angioedema, nasal polyps, or other allergic-type reactions to aspirin or other NSAIDs (severe, sometimes fatal, anaphylactic reactions have been reported)
• Previous serious cutaneous reaction to NSAIDs (e.g., SJS, TEN, DRESS)
• Active or previous peptic ulcer disease, gastrointestinal bleeding, or perforation (including recurrent history)
• Significant gastrointestinal disease predisposing to bleeding
• Severe heart failure
• Severe renal impairment
• Severe hepatic impairment
• Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery
• Concomitant treatment with other NSAIDs or analgesic doses of aspirin, and — per European labeling — concomitant anticoagulant therapy
• Third trimester of pregnancy (risk of premature closure of the fetal ductus arteriosus). The Egyptian Pfizer IM labeling contraindicates use in both the first and third trimesters.

Feldene 0.5% topical gel is additionally contraindicated on broken skin, eczema, infected skin, or mucous membranes.

15. Warnings & Precautions

The U.S. FDA label carries Boxed Warnings for cardiovascular and gastrointestinal events, common to all systemic NSAIDs:

• Cardiovascular Thrombotic Events. NSAIDs increase the risk of serious cardiovascular thrombotic events — including myocardial infarction and stroke — which can be fatal. Risk may occur early in treatment and increase with duration. Avoid in recent MI unless benefits outweigh the risk.
• Gastrointestinal Bleeding, Ulceration, and Perforation. These events can occur at any time, with or without warning symptoms. Only about 1 in 5 patients with a serious upper GI event is symptomatic beforehand. Risk is more than 10-fold higher with prior history of ulcer or GI bleeding. Concomitant oral corticosteroids, anticoagulants, antiplatelets, SSRIs/SNRIs, smoking, alcohol excess, and older age further increase risk.

Other important warnings and precautions:

• Hepatotoxicity. ALT/AST elevations >3× ULN occur in approximately 1% of patients; rare severe hepatic injury, fulminant hepatitis, and liver failure have been reported. Discontinue if abnormal LFTs persist or worsen.
• Hypertension. May cause new-onset or worsening hypertension and may blunt the response to ACE inhibitors, ARBs, thiazide, or loop diuretics. Monitor blood pressure.
• Heart Failure and Edema. Approximately two-fold increase in hospitalizations for heart failure has been observed with NSAIDs; fluid retention and edema may occur.
• Renal Toxicity and Hyperkalemia. Long-term NSAID use has resulted in renal papillary necrosis. Dose-dependent reduction in renal prostaglandins can precipitate renal decompensation, especially in patients with pre-existing renal impairment, dehydration, heart failure, liver dysfunction, the elderly, or those on diuretics/ACE inhibitors/ARBs. Hyperkalemia may occur even in patients without underlying renal impairment.
• Anaphylactic Reactions. May occur in patients with or without previously known hypersensitivity, and in aspirin-sensitive asthma phenotype.
• Aspirin-sensitive Asthma. Piroxicam is contraindicated in this phenotype.
• Serious Skin Reactions. Piroxicam has been associated with exfoliative dermatitis, Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme, fixed drug eruption, and photosensitivity — some fatal. Risk is highest early in treatment. Discontinue at the first sign of a suspicious rash or mucosal reaction; do not rechallenge.
• DRESS. Drug Reaction with Eosinophilia and Systemic Symptoms — potentially fatal multiorgan hypersensitivity — has been reported.
• Fetal Toxicity. NSAIDs at approximately 20 weeks of pregnancy or later may cause fetal renal dysfunction and oligohydramnios; use at ~30 weeks or later may cause premature closure of the fetal ductus arteriosus. Avoid accordingly (see Section 18).
• Hematologic Toxicity. Anemia; increased bleeding risk, especially with coagulation disorders, warfarin, direct oral anticoagulants, aspirin, or SSRIs/SNRIs.
• Masking of Inflammation and Fever. Antipyretic/anti-inflammatory activity may mask developing infection.
• Ophthalmologic Effects. Any new visual disturbance warrants ophthalmic evaluation.
• CYP2C9 Poor Metabolizers. May develop substantially higher systemic exposure; use with caution and consider dose reduction. Co-administration with CYP2C9 inhibitors (e.g., fluconazole) increases exposure.
• Topical Gel is Not Risk-Free. Systemic exposure is much lower than with oral use but not zero; systemic NSAID adverse effects can still occur with extensive application, broken skin, prolonged use, or concomitant systemic NSAIDs.

16. Drug Interactions

Clinically significant interactions include:

• Drugs that interfere with hemostasis (warfarin and other oral anticoagulants, direct oral anticoagulants, antiplatelets, aspirin, SSRIs/SNRIs) — synergistic bleeding risk; monitor closely, and avoid the combination where possible.
• Analgesic doses of aspirin — no added therapeutic benefit; significantly increased GI toxicity. Piroxicam may also interfere with the antiplatelet effect of low-dose aspirin and is not a substitute for cardiovascular-protective aspirin.
• ACE inhibitors, ARBs, beta-blockers — may reduce antihypertensive effect. In the elderly, volume-depleted patients, or those with impaired renal function, combination with ACEi/ARB may precipitate acute renal failure (usually reversible). Monitor blood pressure and renal function.
• Diuretics (loop and thiazide) — reduced natriuretic and antihypertensive effect; monitor for worsening renal function.
• Digoxin — piroxicam may increase serum digoxin concentration and prolong its half-life; monitor levels.
• Lithium — reduced renal lithium clearance and increased plasma concentration (~15% increase, ~20% clearance reduction); monitor for toxicity.
• Methotrexate — increased risk of methotrexate toxicity (neutropenia, thrombocytopenia, renal dysfunction), particularly with high-dose methotrexate or renal impairment.
• Cyclosporine and tacrolimus — increased risk of nephrotoxicity.
• Other NSAIDs and salicylates — increased GI toxicity without added benefit; not recommended.
• Pemetrexed — increased risk of myelosuppression, renal, and GI toxicity. For long half-life NSAIDs such as piroxicam, interrupt for at least 5 days before, on the day of, and 2 days after pemetrexed administration.
• Highly protein-bound drugs — potential displacement interactions; adjust monitoring as clinically appropriate.
• Corticosteroids — increased risk of GI ulceration and bleeding.
• Alcohol — increases the risk of GI irritation and bleeding.

17. Side Effects

Common (incidence >1–10% in clinical trials):

Nausea, dyspepsia/heartburn, abdominal pain, constipation, diarrhea, flatulence, vomiting, headache, dizziness, vertigo, edema/fluid retention, pruritus, rash, tinnitus, and — less commonly — palpitations, stomatitis, drowsiness, and blurred vision.

Serious and postmarketing adverse reactions (frequency not always reliably estimated):

• Gastrointestinal: gastritis, esophagitis, glossitis, gastric or intestinal ulceration, GI bleeding, hematemesis, melena, rectal bleeding, intestinal perforation, pancreatitis, hepatitis, jaundice, elevated liver enzymes, fulminant hepatic failure.
• Cardiovascular: hypertension, tachycardia, arrhythmias, congestive heart failure, exacerbation of angina, myocardial infarction, stroke, hypotension, syncope, vasculitis.
• Renal/Urogenital: abnormal renal function, interstitial nephritis, glomerulonephritis, nephrotic syndrome, renal papillary necrosis, hyperkalemia, hematuria, proteinuria, oliguria/polyuria, acute renal failure.
• Hematologic: anemia, hemolytic anemia, aplastic anemia, pancytopenia, leukopenia, agranulocytosis, thrombocytopenia, eosinophilia, prolonged bleeding time, purpura, ecchymosis, epistaxis.
• Dermatologic/hypersensitivity: anaphylaxis, angioedema, urticaria, DRESS, Stevens–Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, fixed drug eruption, photosensitivity, alopecia.
• Neurologic/psychiatric: anxiety, confusion, depression, insomnia, abnormal dreams, paresthesia, somnolence, tremor, convulsions, aseptic meningitis, hallucinations, coma.
• Metabolic: weight change, fluid retention, hyperglycemia, hypoglycemia.
• Special senses: conjunctivitis, hearing impairment, swollen eyes.
• Reproductive: reversible decrease in female fertility.
• Injection site (IM): local pain and, rarely, sterile abscess or fat necrosis.
• Topical gel: local irritation, burning, erythema, contact dermatitis, photosensitivity; systemic NSAID effects are rare but possible with extensive/prolonged use.

18. Use in Special Populations

Pregnancy.
U.S. FDA labeling: NSAID use at ~20–30 weeks may cause fetal renal dysfunction and oligohydramnios — if use is deemed necessary, limit to the lowest effective dose for the shortest duration, and consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours. Avoid NSAIDs at ~30 weeks and later due to premature ductus arteriosus closure.
European and Egyptian Pfizer IM product information are more restrictive, contraindicating piroxicam in the third trimester, and in the case of the Egyptian IM label, in both the first and third trimesters.
Follow the applicable local product label and obstetric guidance.

Lactation. Piroxicam is detected in breast milk at approximately 1–3% of maternal plasma concentration. The UK SmPC does not recommend Feldene during breastfeeding because infant safety has not been adequately established. If used short-term, monitor the infant.

Fertility. NSAIDs are associated with reversible impairment of ovulation and female fertility. Consider withdrawal in women having difficulty conceiving or undergoing infertility evaluation.

Pediatric Use. Safety and effectiveness of systemic piroxicam have not been established in patients under 18 years in the U.S. label. The Egyptian Pfizer IM information restricts use to patients over 16 years; the Egyptian topical gel labeling permits use in adults and children over 15 years.

Geriatric Use. Older adults are at greater risk of serious GI, cardiovascular, renal, and hepatic adverse effects; most fatal GI events in postmarketing reports occurred in elderly or debilitated patients. The Egyptian Pfizer IM information recommends starting at 10 mg/day in patients over 60 years, reserving 20 mg/day for insufficient response and only for short-term use, and states that piroxicam should not be used in patients over 80 years of age. Use the lowest effective dose and monitor closely; accumulation is greater because of the 50-hour half-life.

Renal Impairment. Avoid in advanced renal disease unless benefits clearly outweigh risks. Severe renal failure is a contraindication in the Egyptian IM label. Monitor renal function.

Hepatic Impairment. Use cautiously with laboratory monitoring; severe hepatic dysfunction increases the risk of GI bleeding and renal failure. Severe hepatic failure is a contraindication in the Egyptian IM label.

Pharmacogenomics. CYP2C9 poor metabolizers (e.g., *3/*3 genotype) have substantially higher systemic exposure; consider dose reduction. Concomitant CYP2C9 inhibitors (e.g., fluconazole) also increase exposure.

19. Storage Conditions

Storage requirements are formulation-specific — always follow the storage statement on the specific package:

• Oral capsules (10 mg / 20 mg): store below 30 °C, in a dry place, protected from moisture and light, in the original tightly closed container.
• Feldene Flash / Melt 20 mg (orodispersible tablets): store below 25 °C; protect from humidity.
• Suppositories: store below 25 °C; may be refrigerated (2–8 °C) in hot climates; do not freeze.
• IM ampoules (20 mg/mL): store below 25 °C; protect from light; do not freeze.
• Feldene 0.5% topical gel: according to the Egyptian Pfizer product information, store at or below 30 °C; do not freeze; keep the tube tightly closed.

Keep all formulations out of the reach and sight of children.

20. Additional Sections

Overdose. Manifestations may include lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding, hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, seizures, and anaphylactoid reactions. Management is symptomatic and supportive; there is no specific antidote. Activated charcoal may be considered within about 4 hours of significant ingestion (>5× therapeutic dose). Forced diuresis, urinary alkalinization, hemodialysis, and hemoperfusion are not useful because of piroxicam’s high protein binding. Contact a Poison Control Center.

Feldene Flash/Melt vs. conventional capsule. Flash/Melt contains a piroxicam-β-cyclodextrin complex enabling faster dissolution and absorption (Tmax ~1.4–2 hours versus 3–5 hours for the capsule). Onset of analgesia is faster, while the overall efficacy, daily dose limit, and safety profile are the same. It is useful when rapid onset is desired or when patients have swallowing difficulty.

Laboratory monitoring. Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms, periodic monitoring of complete blood count and chemistry/liver profile is recommended in long-term users, particularly in high-risk patients.

Patient counseling. Advise patients to seek prompt medical attention for chest pain, shortness of breath, sudden weakness or slurred speech, black tarry stools, hematemesis, unexplained swelling or weight gain, skin rash or blistering, mucosal lesions, fever with rash and lymphadenopathy (possible DRESS), jaundice, or visual disturbances. Avoid concomitant NSAIDs and limit alcohol. Inform patients of the pregnancy risks and the importance of not exceeding the recommended daily dose across all formulations.

Regulatory context. The European Medicines Agency’s Article 31 referral (2007) on piroxicam-containing medicines concluded that piroxicam should be restricted to second-line use for chronic inflammatory conditions, with the maximum daily dose limited to 20 mg, treatment reviewed after two weeks, and gastroprotection considered in high-risk patients.

21. Frequently Asked Questions (FAQ)

1. What is Feldene used for? Systemic Feldene (piroxicam) is FDA-approved for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Several non-U.S. labels also include ankylosing spondylitis; in Egypt it is also used for acute musculoskeletal conditions, dysmenorrhea, and, as a 0.5% topical gel, for sprains and localized musculoskeletal pain.

2. Is Feldene an antibiotic? No. Piroxicam is an NSAID; it does not treat bacterial, viral, fungal, or parasitic infections.

3. What is the usual adult dose? The commonly recommended maximum for systemic treatment is 20 mg once daily, using the lowest effective dose for the shortest duration.

4. How long does Feldene stay in the body? The plasma half-life is approximately 50 hours, substantially longer than most NSAIDs. Steady state is reached only after 7–12 days, so the full clinical effect (and adverse effects) may accumulate for up to 2 weeks after starting, and may persist for several days after stopping.

5. Can I take Feldene on an empty stomach? It is well absorbed either way, but taking it with or after food and a full glass of water reduces gastric irritation. Avoid lying down for 15–30 minutes after an oral dose.

6. Is Feldene Flash stronger than the regular capsule? No. Flash/Melt contains the same active ingredient at the same strength (20 mg). It dissolves and is absorbed faster, so pain relief begins earlier; pharmacokinetic studies show bioequivalence to the conventional capsule with repeated dosing.

7. Can Feldene 10 mg and 20 mg be taken together? Only if specifically prescribed. They contain the same drug, and the total systemic daily dose should not exceed the recommended maximum (generally 20 mg/day).

8. Is the topical gel safer than the tablets? Systemic exposure from 0.5% gel is substantially lower, so GI, cardiovascular, and renal risks are considerably reduced — but not eliminated. Local skin irritation and photosensitivity can occur, and extensive application together with oral NSAIDs should be avoided.

9. Can Feldene be taken with ibuprofen, diclofenac, naproxen, or aspirin? Generally no. Combining systemic piroxicam with another NSAID or with analgesic doses of aspirin increases adverse effects without added benefit. If additional analgesia is needed, paracetamol/acetaminophen is generally preferred — consult a physician. Piroxicam is not a substitute for cardiovascular-protective low-dose aspirin.

10. Can Feldene be used during pregnancy or breastfeeding? Avoid NSAIDs from about 20 weeks of pregnancy due to the risk of fetal renal dysfunction and oligohydramnios, and avoid from about 30 weeks due to premature closure of the ductus arteriosus. The European and Egyptian labels are more restrictive (third-trimester contraindication; the Egyptian IM label also contraindicates the first trimester). Piroxicam passes into breast milk at low levels; UK labeling does not recommend breastfeeding while on Feldene.

11. Who should not take piroxicam? Patients with hypersensitivity to piroxicam or other NSAIDs (including NSAID-induced asthma, urticaria, or angioedema), active or previous peptic ulcer/GI bleeding, severe heart, renal, or hepatic failure, previous SJS/TEN/DRESS to any NSAID, patients undergoing CABG surgery, and in contraindicated stages of pregnancy per the local label.

12. Why is piroxicam considered higher risk than some other NSAIDs? The EMA’s 2007 review found piroxicam carries a relatively higher risk of serious gastrointestinal and cutaneous reactions than some other non-selective NSAIDs; consequently, it should be second-line for chronic inflammatory conditions, used at the lowest effective dose, with gastroprotection considered in high-risk patients.

13. What are the most dangerous warning signs to watch for? Seek urgent medical care for: vomiting blood or black/tarry stools; severe or persistent abdominal pain; chest pain or symptoms of heart attack or stroke; difficulty breathing or facial/throat swelling; rapidly spreading rash, blistering, or mucosal lesions; jaundice or symptoms suggesting liver injury; markedly reduced urine output.

14. What if I miss a dose? Take the missed dose as soon as you remember, unless it is nearly time for the next dose — in which case skip the missed dose. Never take a double dose. Because of the long half-life, a single missed dose has limited impact on plasma levels.

22. References

U.S. Food and Drug Administration — FELDENE® (piroxicam) capsules, U.S. Prescribing Information, Pfizer, most recent labeling revision November 2024 (supplement approval 21 November 2024; sNDA 018147/S-053). Includes boxed warnings for cardiovascular thrombotic events and gastrointestinal bleeding, ulceration, and perforation.
DailyMed / National Library of Medicine — Piroxicam (FELDENE) capsule labeling, current U.S. product information.
electronic Medicines Compendium (emc) — Feldene 10 mg Capsules SmPC (Pfizer Limited, UK), updated 5 September 2025.
electronic Medicines Compendium (emc) — Feldene Melt 20 mg Tablets SmPC (Pfizer Limited, UK), updated 8 September 2025.
Pfizer — Feldene 20 mg/mL IM Injection, Egypt, Summary of Product Characteristics, March 2022.
Pfizer — Feldene 0.5% Topical Gel, Egypt, product information, March 2022.
European Medicines Agency — Piroxicam-containing medicines, CHMP Article 31 referral (2007), restricting piroxicam to second-line use in chronic inflammatory conditions and limiting the maximum daily dose.
Egyptian Drug Authority (EDA) — Registered Medicines Database, the authoritative source for the current Egyptian registration status, MAH, manufacturer, strength, and pack size.
PharmGKB / ClinPGx — CYP2C9 annotation of the FDA piroxicam label, on CYP2C9 poor-metabolizer pharmacogenomics.
WebMD — Piroxicam (Feldene) drug monograph (referencing Pfizer U.S. Prescribing Information, November 2024).